Could a Two-Drug punch wipe out melanoma before surgery?
NCT ID NCT04401995
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 2 pilot study tests whether adding the investigational drug vidutolimod to the immunotherapy nivolumab can destroy more melanoma tumors in lymph nodes or nearby skin areas before surgery. Participants have stage IIIB/C/D melanoma that has spread but not to distant organs. The study also uses a special PET scan to track immune activity. The goal is to see if the combination leads to a higher rate of complete tumor disappearance compared to nivolumab alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vidutolimod (CMP-001) and Nivolumab
What this could lead to
If successful, this combination could offer a more effective pre-surgery treatment for advanced melanoma, potentially reducing the risk of cancer spread.
What could go wrong
This is a small, early-phase pilot study with only 9 participants, so results may not apply broadly. The combination may also cause additional side effects compared to nivolumab alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- NEOSENT: Anti-PD-1 Timing in High-Risk Melanoma NCT07680699
- TRK-950 Combination Therapy for Advanced Solid T NCT03872947
- EMPOWER Trial: ePRO Monitoring for Melanoma Side NCT07660666
- SPECT Imaging Targeting LRRC15 in Tumors - NCT07651020
- Melanoma SLNB Decision Aid Trial | NCT07653087
- FLARE Skin Cancer Prevention for Kids of Melanom NCT04201223
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States